BMX, a specific HDAC8 inhibitor, with TMZ for advanced CRC therapy: a novel synergic effect to elicit p53-, β-catenin- and MGMT-dependent apoptotic cell death

BACKGROUND: Despite advances in treatment, patients with refractory colorectal cancer (CRC) still have poor long-term survival, so there is a need for more effective therapeutic options. METHODS: To evaluate the HDAC8 inhibition efficacy as a CRC treatment, we examined the effects of various HDAC8 i...

Descripción completa

Detalles Bibliográficos
Autores principales: Ko, Huey-Jiun, Chiou, Shean-Jaw, Tsai, Cheng-Yu, Loh, Joon-Khim, Lin, Xin-Yi, Tran, Thu-Ha, Hou, Chia-Chung, Cheng, Tai-Shan, Lai, Jin-Mei, Chang, Peter Mu-Hsin, Wang, Feng-Sheng, Su, Chun-Li, Huang, Chi-Ying F., Hong, Yi-Ren
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9793577/
https://www.ncbi.nlm.nih.gov/pubmed/36575468
http://dx.doi.org/10.1186/s12964-022-01007-x

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9793577/
https://www.ncbi.nlm.nih.gov/pubmed/36575468
http://dx.doi.org/10.1186/s12964-022-01007-x

Ejemplares similares